Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Axsome Therapeutics Rocketed 78.8% Higher in March

By Cory Renauer - Apr 8, 2019 at 9:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This tiny biotech may have found the tastiest low-hanging fruit the industry's ever seen.

What happened

Shares of Axsome Therapeutics (AXSM -2.99%), a clinical-stage biopharmaceutical company, soared 78.8% higher in March, according to data from S&P Global Market Intelligence. A handful of positive developments related to a new version of an old depression drug did the trick last month.

So what 

In January, we learned that Axsome's AXS-05 outperformed standard treatment, and in March, more investors began to notice. Axsome was largely ignored, possibly because as its lead candidate, AXS-05 is simply bupropion plus dextromethorphan, the active ingredients in Wellbutrin and over-the-counter cough suppressants.

Man in a suit wearing a jetpack on his back with his arms up as if getting ready to fly.

Image source: Getty Images.

AXS-05 isn't the most innovative new drug candidate, but there's a chance it could begin generating nine-figure sales in a couple of years as a new option for patients with treatment-resistant major depressive disorder (MDD). Physicians are already comfortable with bupropion and use it to treat seasonal affective disorder and attention deficit disorder. Under the brand name Zyban, it's also used to help smokers drop the habit. 

Physicians have been warning patients not to mix Wellbutrin with dextromethorphan for decades because they amplify each other's effects. There's a good chance that mid-stage studies Axsome's running with AXS-05 in other indications commonly treated with Wellbutrin can succeed as well.

Now what

Johnson & Johnson (JNJ -0.98%) recently earned approval to market ketamine, the often-abused party drug, to patients with treatment-resistant depression under the brand name Spravato. If AXS-05's ongoing phase 3 study succeeds, tiny Axsome could end up competing with the world's largest healthcare company.

There should be enough room to grow for Johnson & Johnson and Axsome. The National Institutes of Health thinks 16 million Americans experience MDD each year and most of them don't respond to their first therapy. 

It won't be long before we know if AXS-05 can become a popular new option for a huge underserved group. Axsome is currently enrolling patients with treatment-resistant depression into a phase 3 study with AXS-05 that should deliver results before the end of June. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
$25.27 (-2.99%) $0.78
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.62 (-0.98%) $-1.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.